- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Zydus Lifesciences reported strong Q2 FY26, with total revenues rising 17% YoY to ₹6,123.2 Cr and net profit jumping 38% YoY to ₹1,258.6 Cr. EBITDA margin expanded by 500 bps to 32.9%.
Business performance was robust across segments. India formulations grew 9% YoY, outperforming the market, fueled by its chronic portfolio. US formulations delivered 13.5% YoY growth with new product launches and 4 ANDA approvals. International Markets surged 39.4% YoY due to strong execution. Consumer Wellness made its first international acquisition, acquiring UK-based Comfort Click Ltd, expanding its global footprint.
Innovation is a key growth driver. The company announced positive Phase 2(b)/3 clinical trial results for Saroglitazar Magnesium in PBC for the US market, with plans to file its New Drug Application (NDA) in Q4 FY26. It also received approval to initiate Phase II clinical trials for its Bivalent Typhoid Conjugate Vaccine in India.